Blood Glucose Monitoring Systems Market Summary
- The blood glucose monitoring systems market was valued at USD 12.12 billion in 2024 and expected to reach USD 18.89 billion by 2032.
- Blood Glucose Monitoring Systems Market is expected to grow at a CAGR of 7.72% during the forecast period from 2025 to 2032.
Blood Glucose Monitoring Systems Market Insight and Trends
- The blood glucose monitoring systems market is expanding rapidly due to the rising prevalence of lifestyle style disorders such as diabetes and impaired glucose tolerance, growing product launches and approvals by key players, and a rising preference for minimally invasive techniques that are expected to significantly drive the demand for blood glucose monitoring systems from 2025 to 2032.
- Blood Glucose Monitoring Systems Companies include Medtronic, Abbott, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Dexcom Inc., ARKRAY, Inc., Senseonics, WaveForm Technologies, Inc., B. Braun Melsungen AG, Ascensia Diabetes Care Holdings AG., Ypsomed, i-SENS, Inc., Intuity Medical, Inc., ACON Laboratories, Inc., Prodigy Diabetes Care, LLC, Sinocare, Rossmax International Ltd., Menarini Diagnostics s.r.l., Bionime Corporation., Nemaura., and others.
- In the product type segment of blood glucose monitoring systems, the continuous glucose monitoring systems category is expected to have a significant revenue share in the year 2023.
- North America is expected to dominate the blood glucose monitoring systems market in the year 2023 and is expected to do the same during the forecast period from 2025 to 2032.
Blood Glucose Monitoring Systems Market Size and Forecasts
- 2024 Market Size: USD 12.12 billion
- 2032 Projected Market Size: USD 18.89 billion
- Growth Rate (2024-2030): 7.72% CAGR
- Largest Market: North America
- Fastest Growing Market: Asia-Pacific
- Market Structure: Moderately Consolidated
Factors Affecting the Blood Glucose Monitoring Systems Market Growth
Rising Global Prevalence of Diabetes
The rapidly increasing incidence of Type 1, Type 2, and gestational diabetes is the strongest driver of demand for blood glucose monitoring devices. A larger patient pool directly boosts sales of meters, test strips, and continuous glucose monitoring (CGM) systems.
Shift Toward Continuous Glucose Monitoring (CGM)
The adoption of real-time and intermittently scanned CGMs is accelerating due to better accuracy, convenience, and improved patient adherence. Their role in therapy optimization, especially among insulin-dependent patients, significantly increases market revenue.
Technological Advancements
Technological advancements in blood glucose monitoring systems include improved sensor accuracy, longer wear durations, smartphone connectivity, cloud-based data sharing, and AI-driven predictive insights. Innovations such as minimally invasive and needle-free sensors enhance user comfort and adherence, driving wider adoption of continuous and self-monitoring solutions for better diabetes management.
Increasing Awareness of Early Diagnosis & Self-Management
Greater emphasis on self-monitoring of blood glucose (SMBG), preventive care programs, and education initiatives are encouraging regular monitoring, fueling product demand.
Favorable Reimbursement Policies in Major Markets
Coverage for test strips, meters, and CGM systems particularly in the US, EU, and Japan reduces out-of-pocket costs and supports higher adoption rates.
Growth in Geriatric Population
Older adults have higher diabetes prevalence and require continuous monitoring, boosting both SMBG and CGM usage.
Integration of Digital Health Platforms
Availability of cloud-based data sharing, remote patient monitoring, telehealth platforms, and physician dashboards increases the value proposition of BGMS devices and supports strong adoption, especially in chronic disease management programs.
Blood Glucose Monitoring Systems Market by Product Type (Self-Monitoring Blood Glucose Systems and Continuous Glucose Monitoring Systems), Modality (Wearable and Non-Wearable), End-User (Hospitals, Home Care Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to advance at a respectable CAGR forecast till 2032 owing to the rising prevalence of lifestyle style disorders and increasing product developmental activities worldwide
The blood glucose monitoring systems market was valued at USD 12.12 billion in 2024, growing at a CAGR of 7.72% during the forecast period from 2025 to 2032 to reach USD 18.89 billion by 2032. The blood glucose monitoring systems market is expanding rapidly due to the rising prevalence of lifestyle style disorders such as diabetes and impaired glucose tolerance, growing product launches and approvals by key players, and a rising preference for minimally invasive techniques that are expected to significantly drive the demand for blood glucose monitoring systems from 2025 to 2032.
Blood Glucose Monitoring Systems Market Dynamics:
According to data from the International Diabetes Federation (2022), in 2021, 537 million adults aged 20-79 were living with diabetes, equating to about 1 in 10 individuals. This number is expected to increase to 643 million by 2032 and reach 783 million by 2045. Notably, over 75% of adults with diabetes reside in low- and middle-income countries. Additionally, 541 million adults have impaired glucose tolerance, putting them at elevated risk for developing type 2 diabetes.
Blood glucose monitoring systems are essential tools for managing diabetes and preventing its progression, particularly in low- and middle-income countries where the prevalence is high. These systems enable individuals to regularly check and manage their blood glucose levels, allowing for timely adjustments in diet, exercise, and medication. For those with impaired glucose tolerance, monitoring can help identify early glucose fluctuations and support interventions to prevent the onset of type 2 diabetes. Effective use of these systems can lead to better disease management, reducing complications and improving overall health outcomes.
Moreover, companies are amplifying their production of blood glucose monitoring systems and securing regulatory approvals, thereby strategically expanding their market presence and driving further growth. For instance, in January 2024, Medtronic, a global leader in healthcare technology, announced CE Mark approval for the MiniMed™ 780G system with Simplera Sync™, a disposable, all-in-one continuous glucose monitor that required no fingersticks or overtape. Simplera Sync™ featured an improved user experience with a simple, two-step insertion process.
Therefore, all the factors stated above collectively will drive the overall blood glucose monitoring systems market during the forecast period from 2025 to 2032.
However, false readings or technical errors can lead to incorrect insulin dosing which is associated with hypoglycaemia or hyperglycaemia, availability of alternative options among others may limit their end-user base, thus acting as key constraints limiting the growth of the blood glucose monitoring systems market.
Blood Glucose Monitoring Systems Market Segment Analysis:
Blood Glucose Monitoring Systems Market by Product Type (Self-Monitoring Blood Glucose Systems and Continuous Glucose Monitoring Systems), Modality (Wearable and Non-Wearable), End-User (Hospitals, Home Care Settings, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product type segment of blood glucose monitoring systems, the continuous glucose monitoring systems category is expected to have a significant revenue share in the year 2023. This is due to the key features and widespread application provided by these.
Continuous glucose monitoring systems provide real-time tracking of blood glucose levels by using a small sensor placed under the skin to measure glucose in interstitial fluid. These offer continuous monitoring and can update readings every few minutes, reducing the need for frequent manual checks. Key features include alarms for high or low glucose levels, calibration-free technology, and integration with smartphones and digital health platforms for detailed data analysis and trend visualization.
These systems are especially beneficial for individuals with Type 1 diabetes and Type 2 diabetes, helping them achieve better glycemic control, reduce the risk of hypoglycemia, and optimize insulin therapy through integration with insulin pumps or artificial pancreas systems. Additionally, they are widely used in clinical research to analyze glucose patterns and develop new treatment strategies, making them indispensable for personalized diabetes management and improving patient outcomes.
Rising product developmental activities by regulatory bodies will further boost the market for the same. For example, in June 2024, Abbott announced that the US Food and Drug Administration (FDA) approved two new over-the-counter continuous glucose monitoring systems – Lingo™ and Libre Rio™. These systems were based on Abbott's world-leading FreeStyle Libre® continuous glucose monitoring technology.
Therefore, owing to the above-mentioned factors, the demand for the continuous glucose monitoring category upsurges, owing to which the category is expected to witness considerable growth eventually contributing to the overall growth of the blood glucose monitoring systems market during the forecast period from 2025 to 2032.
Scope of the Blood Glucose Monitoring Systems Market | |
|
Report Metrics |
Details |
|
Study Period |
2022 to 2032 |
|
Forecast Period |
2025-2032 |
|
CAGR |
7.72% (Request Sample To Know More) |
|
Blood Glucose Monitoring Systems Market |
~USD 18.89 billion by 2032 |
|
Key Blood Glucose Monitoring Systemss Companies |
Medtronic, Abbott, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Dexcom Inc., ARKRAY, Inc., Senseonics, WaveForm Technologies, Inc., B. Braun Melsungen AG, Ascensia Diabetes Care Holdings AG., Ypsomed, i-SENS, Inc., Intuity Medical, Inc., ACON Laboratories, Inc., Prodigy Diabetes Care, LLC, Sinocare, Rossmax International Ltd., Menarini Diagnostics s.r.l., Bionime Corporation., Nemaura., and others. |
Blood Glucose Monitoring Systems Regional Analysis
North America is expected to dominate the overall blood glucose monitoring systems market
Among all the regions, North America is expected to dominate the blood glucose monitoring systems market in the year 2023 and is expected to do the same during the forecast period from 2025 to 2032. This is driven by the rising cases of diabetes, advancement in blood glucose monitoring systems, regulatory support, and introduction of innovative products by the key market players that are anticipated to significantly propel market growth for blood glucose monitoring systems from 2025 to 2032.
As per the recent data provided by the Centre for Disease Control and Prevention (2024), in 2021, 38.4 million people of all ages, or 11.6% of the US population had diabetes. Blood glucose monitoring systems are essential tools for managing diabetes, helping individuals regularly check and maintain their blood sugar levels. These systems, including finger-stick glucometers and continuous glucose monitors, enable users to track glucose fluctuations throughout the day. This information allows for timely adjustments in diet, physical activity, and medication to maintain optimal blood sugar levels, prevent complications, and manage diabetes effectively.
Additionally, the increasing number of product development activities in the region by the regulatory bodies is further going to accelerate the growth of the blood glucose monitoring systems market. For instance, in August 2024, Medtronic plc, a global leader in healthcare technology, announced the U.S. Food and Drug Administration (FDA) approved its Simplera™ continuous glucose monitor (CGM). This approval marked the launch of the company's first disposable, all-in-one CGM, which was half the size of previous Medtronic CGMs.
In addition to this in June 2024, Prevounce Health, a leading provider of remote care management software, devices, and services, announced the launch of its first remote blood glucose monitoring device, the Pylo GL1-LTE. The blood glucose meter was clinically validated and connected to multiple cellular networks to ensure reliable data transmission throughout the US.
Therefore, the interplay of all the aforementioned factors above would provide a conducive growth environment for the North America region in the blood glucose monitoring systems market.
Who are the major players in Blood Glucose Monitoring Systems?
The following are the leading companies in Blood Glucose Monitoring Systems. These companies collectively hold the largest Blood Glucose Monitoring Systems market share and dictate industry trends.
Blood Glucose Monitoring Systems Companies
Some of the key blood glucose monitoring systems companies operating in the market include Medtronic, Abbott, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Dexcom Inc., ARKRAY, Inc., Senseonics, WaveForm Technologies, Inc., B. Braun Melsungen AG, Ascensia Diabetes Care Holdings AG., Ypsomed, i-SENS, Inc., Intuity Medical, Inc., ACON Laboratories, Inc., Prodigy Diabetes Care, LLC, Sinocare, Rossmax International Ltd., Menarini Diagnostics s.r.l., Bionime Corporation., Nemaura., and others.
Recent Developmental Activities in the Blood Glucose Monitoring Systems Market:
- In August 2025, Signos launched the Signos Glucose Monitoring System, the first FDA-cleared, over-the-counter glucose monitoring system designed for weight management. The system integrates the Stelo by Dexcom glucose biosensor with an AI-powered platform, providing personalized, real-time insights into how food, activity, stress, and sleep impact metabolic health.
- In September 2024, the Eversense 365 received FDA clearance as an integrated continuous glucose monitoring (iCGM) system for individuals with diabetes. Unlike short-term CGMs that typically last 10 to 14 days, the Eversense 365 features a single sensor that can be used for an entire year, offering minimal disruption to daily life. The launch is anticipated in early Q4 2024.
- In May 2024, Smart Meter launched iGlucose Plus for diabetes management, a cellular-enabled glucose meter that eliminated the need for syncing, pairing, or relying on smartphones and Wi-Fi.
- In February 2024, Dexcom launched its real-time continuous glucose monitoring solution, Dexcom ONE+, in Europe. Dexcom ONE+ was a customizable CGM solution designed to be worn at three different locations on the body.
- In November 2021, Intuity Medical launched the POGO Automatic Blood Glucose Monitoring System for diabetes patients in the US.
- In July 27, 2021, Terumo launched the Dexcom G6 Continuous Glucose Monitoring (CGM) System in Japan, which is manufactured by Dexcom, Inc.
Blood Glucose Monitoring Systems Market Segmentation
Blood Glucose Monitoring Systems Market by Product Type
- Self-Monitoring Blood Glucose Systems
- Continuous Glucose Monitoring Systems
Blood Glucose Monitoring Systems Market by Modality
- Wearable
- Non-Wearable
Blood Glucose Monitoring Systems Market by End-User
- Hospitals
- Home Care Settings
Blood Glucose Monitoring Systems Market by Geography
North America Blood Glucose Monitoring Systems Market
- United States Blood Glucose Monitoring Systems Market
- Canada Blood Glucose Monitoring Systems Market
- Mexico Blood Glucose Monitoring Systems Market
Europe Blood Glucose Monitoring Systems Market
- United Kingdom Blood Glucose Monitoring Systems Market
- Germany Blood Glucose Monitoring Systems Market
- France Blood Glucose Monitoring Systems Market
- Italy Blood Glucose Monitoring Systems Market
- Spain Blood Glucose Monitoring Systems Market
- Rest of Europe
Asia-Pacific Blood Glucose Monitoring Systems Market
- China Blood Glucose Monitoring Systems Market
- Japan Blood Glucose Monitoring Systems Market
- India Blood Glucose Monitoring Systems Market
- Australia Blood Glucose Monitoring Systems Market
- South Korea Blood Glucose Monitoring Systems Market
- Rest of Asia-Pacific
Rest of the World
- South America Blood Glucose Monitoring Systems Market
- Middle East Blood Glucose Monitoring Systems Market
- Africa Blood Glucose Monitoring Systems Market
Blood Glucose Monitoring Systems Market Recent Industry Trends and Milestones (2022–2025) | |
|---|---|
| Category | Key Developments (2022–2025) |
| Product Launches | Launch of next-generation CGM systems with extended sensor wear, improved accuracy, smartphone integration, and reduced calibration requirements; introduction of compact Bluetooth-enabled glucometers for home monitoring. |
| Regulatory Approvals | FDA and CE approvals for advanced real-time CGM devices, integrated insulin delivery systems, and sensor-based monitoring platforms supporting closed-loop diabetes management. |
| Partnerships | Collaborations between device manufacturers, digital health companies, and cloud-platform providers to enhance remote monitoring, data analytics, and AI-driven decision support tools. |
| Acquisitions | Strategic acquisitions of diabetes-focused digital health startups and sensor technology firms to strengthen portfolios in continuous monitoring, wearable devices, and AI-enabled glucose management. |
| Company Strategy | Expansion into emerging markets, portfolio diversification toward minimally invasive and long-wear sensors, and increased investment in R&D for next-generation CGM and connected SMBG devices. |
| Emerging Technology | Advancements in needle-free and implantable sensors, integration with AI algorithms for predictive glucose alerts, cloud-linked monitoring ecosystems, and development of fully automated closed-loop systems. |
Impact Analysis
What is the impact of AI on the Blood Glucose Monitoring Systems?
AI-Powered Innovations and Applications:
-
Predictive analytics & personalized alerts: AI models analyze CGM trends to predict hypoglycaemia/hyperglycaemia and issue early warnings, reducing acute events and hospitalisations.
-
Closed-loop & adaptive insulin dosing: Machine-learning algorithms enable tighter automated insulin delivery by learning individual response patterns, improving time-in-range
-
Patient engagement & behavioral coaching: AI synthesizes CGM + lifestyle inputs (meals, activity) to generate tailored, automated coaching—boosting adherence and self-management
-
Device performance & signal processing: AI improves sensor calibration, noise reduction, and anomalous-signal detection—raising effective accuracy of minimally invasive and wearable sensors.
Market & Commercial Impact:
-
Faster adoption of CGM and hybrid closed-loop systems as clinical outcomes and user experience improve; higher ARPU from subscription analytics and value-added software.
-
New revenue streams (SaaS analytics, clinician dashboards, API partnerships) and increased M&A interest in AI start-ups focused on metabolic health.
Risks & Barriers:
-
Regulatory scrutiny on algorithm transparency, clinical validation, and cybersecurity; payers demand real-world outcome proof before reimbursing software-driven services.
U.S. Tariff Impact Analysis on Blood Glucose Monitoring Systems
Current trade context & immediate effects:
-
Recent U.S. tariff measures and changing exclusions have created uncertainty for medical device imports; some medical/industrial categories received short-term exclusions, but broader tariff regimes remain a cost risk.
-
Analysts and industry sources warn that tariffs (announced in 2025) can materially raise device and component costs—driving higher prices for CGMs, meters, and strips in the U.S. if exemptions don’t apply.
Supply-chain & manufacturing implications:
-
Tariffs on Chinese and other imports increase component costs (sensors, PCBs, semiconductors), incentivizing near-shoring, dual-sourcing, or vertical integration. Manufacturers may absorb some costs short-term but will likely pass on prices or localize production mid-term.
Market consequences & recommendations:
-
Short term: Margin pressure for import-reliant players; potential price increases reducing affordability in sensitive segments (SaaS/consumer CGM).
-
Medium term: Acceleration of manufacturing relocation to US/USMCA partners, greater inventory buffers, and renegotiated supplier contracts
-
Strategic moves for companies: pursue tariff-mitigation (HTS classification review, exclusion petitions), diversify suppliers, increase regional assembly, and develop higher-margin software services to offset hardware cost inflation.
Key Takeaways from the Blood Glucose Monitoring Systems Market Report Study
- Market size analysis for current blood glucose monitoring systems market size (2023), and market forecast for 6 years (2025 to 2032)
- Top key product/services developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
- Key companies dominating the blood glucose monitoring systems market
- Various opportunities available for the other competitors in the blood glucose monitoring systems market space
- What are the top-performing segments in 2023? How these segments will perform in 2032?
- Which are the top-performing regions and countries in the current blood glucose monitoring systems market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for blood glucose monitoring systems market growth in the coming future?
Target audience who can be benefited from this Blood Glucose Monitoring Systems Market Report Study
- Blood glucose monitoring systems product providers
- Research organizations and consulting companies
- Blood glucose monitoring systems-related organizations, associations, forums, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and traders dealing in blood glucose monitoring systems
- Various end-users who want to know more about the blood glucose monitoring systems market and the latest developments in the blood glucose monitoring systems market
